ID: ALA482498

Max Phase: Preclinical

Molecular Formula: C26H20N2O8

Molecular Weight: 488.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)/C=C/C(=O)Nc1ccc(Oc2cccc(Oc3ccc(NC(=O)/C=C/C(=O)O)cc3)c2)cc1

Standard InChI:  InChI=1S/C26H20N2O8/c29-23(12-14-25(31)32)27-17-4-8-19(9-5-17)35-21-2-1-3-22(16-21)36-20-10-6-18(7-11-20)28-24(30)13-15-26(33)34/h1-16H,(H,27,29)(H,28,30)(H,31,32)(H,33,34)/b14-12+,15-13+

Standard InChI Key:  HZFPOTBCYPWQSH-QUMQEAAQSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 488.45

Molecular Weight (Monoisotopic): 488.1220

AlogP: 4.43

#Rotatable Bonds: 10

Polar Surface Area: 151.26

Molecular Species: ACID

HBA: 6

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 2.64

CX Basic pKa:

CX LogP: 3.81

CX LogD: -3.15

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.31

Np Likeness Score: -0.39

References

1. Fells JI, Tsukahara R, Fujiwara Y, Liu J, Perygin DH, Osborne DA, Tigyi G, Parrill AL..  (2008)  Identification of non-lipid LPA3 antagonists by virtual screening.,  16  (11): [PMID:18467108] [10.1016/j.bmc.2008.04.035]

2. Fells JI, Tsukahara R, Liu J, Tigyi G, Parrill AL..  (2009)  Structure-based drug design identifies novel LPA3 antagonists.,  17  (21): [PMID:19800804] [10.1016/j.bmc.2009.09.022]

Source

Source(1):

• Scientific Literature